MedTrace Logo

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-03-03

No results posted yet for this study

Summary

This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.

Conditions

Interventions

DRUG

Reduced Toxicity Ablative Regimen

* Anti-thymocyte Globulin (ATG) * Fludarabine * Busulfan * Stem Cell Infusion Day 0

DRUG

Reduced Intensity Preparative Regimen

* Alemtuzumab * Cyclophosphamide * Fludarabine * Total Body Irradiation (TBI) * Stem Cell Infusion Day 0

DRUG

Myeloablative Preparative Regimen

* Alemtuzumab * Cyclophosphamide * Busulfan * Stem Cell Infusion Day 0

Sponsors & Collaborators

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Ashish Gupta, MBBS, MPH · Masonic Cancer Center, University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-02
Primary Completion
2024-11-21
Completion
2024-11-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02179359 on ClinicalTrials.gov